UnknownNot Applicable

Effect of Genetic and Epigenetic Factors on the Clinical Response and Toxicity to Doxorubicin Among Egyptian Breast Cancer Patients

Egypt200 participantsStarted 2020-08-01

Plain-language summary

Recent advances in technologies, such as microarray and high-throughput sequencing, represented a deeper understanding of molecular biology, especially noncoding RNA (ncRNA). It was found that there are only \<2 % of the total genome sequence as protein-coding genes while at least 98 % of the genome are transcribed into ncRNA. In the past, non-protein-coding RNAs were known as "transcription noise," but now it is obvious that ncRNAs play a crucial regulatory role in cell differentiation and organism growth and metabolism.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Metastatic and localized breast cancer patients treated with Doxorubicin among chemotherapeutic protocol. * Measurable disease. * Age of 18 years to 80 years. * The women of childbearing age must use an effective contraception for the duration of the study. Exclusion Criteria: * Breast cancer patients who had undergone radiotherapy or chemotherapy. * Pregnant and lactating females. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to chemotherapeutic agents used. * Any other medical or psychiatric condition or severe or chronic laboratory abnormality making the inclusion of the patient in the study inappropriate in the opinion of the investigator.

What they're measuring

Cardiotoxicity

Timeframe: 6 months

Trial details

NCT IDNCT05733026

SponsorAin Shams University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-01-01

Contact for this trial

Neven Sarhan, PhD

+201021944422 sarhanneven@gmail.com

View on ClinicalTrials.gov More Breast Cancer trials